Insmed (INSM) Common Equity (2010 - 2026)

Insmed's Common Equity history runs 17 years deep, the most recent figure standing at $704.9 million for Q1 2026.

• In Q1 2026, Common Equity rose 610.83% year-over-year to $704.9 million; the TTM figure through Mar 2026 stood at $704.9 million (up 610.83% YoY), while the FY2025 annual figure was $739.0 million, up 158.95% from the prior year.
• Common Equity was $704.9 million for Q1 2026 at Insmed, down from $739.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.2 billion in Q2 2025 to a low of -$464.8 million in Q1 2024.
• Historically, Common Equity has averaged $204.8 million across 5 years, with a median of $88.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Common Equity plunged 940.93% in 2024, then soared 3119.47% in 2025.
• A 5-year view of Common Equity shows it stood at $88.0 million in 2022, then sank by 477.4% to -$331.9 million in 2023, then surged by 185.98% to $285.4 million in 2024, then surged by 158.95% to $739.0 million in 2025, then fell by 4.62% to $704.9 million in 2026.
• The last three Common Equity figures came in at $704.9 million (Q1 2026), $739.0 million (Q4 2025), and $945.6 million (Q3 2025), per Business Quant data.